ArticleArchives of rheumatology2026
Assessment of the Concomitance of Fibromyalgia in Patients with Axial Spondyloarthritis and Rheumatoid Arthritis.
Article in Archives of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Fibromyalgia as a Confounder of Disease Activity Assessment in Inflammatory Arthritis.Archives of rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsFibromyalgia (FM) is a chronic pain condition in which patients experience diffuse musculoskeletal discomfort accompanied by marked fatigue, non-restorative sleep patterns, and cognitive complaints. Individuals with FM exhibit elevated inflammatory cytokines. The aim was to investigate the prevalence of FM in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) and to evaluate the effects of biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) on FM. MATERIALS AND
methodsPatients were enrolled in the study, including spondyloarthritis and RA patients. Disease activity in RA patients was assessed using the Disease Activity Score-28 scores. For SpA patients, the Bath Ankylosing Spondylitis Disease Activity Index and the Bath Ankylosing Spondylitis Metrology Index were used to evaluate disease activity and structural damage. Patients were evaluated for FM according to the 1990 American College of Rheumatology classification criteria. The Fibromyalgia Impact Questionnaire was administered for FM severity.
resultsThere was no significant difference in the prevalence of FM between the RA and SpA groups (P = .942). The prevalence of FM was significantly higher among patients not receiving b/tsDMARDs compared to those who were (P = .033). In the SpA subgroup, no significant difference in FM prevalence was observed between patients using and not using b/ tsDMARDs (P = .314). However, in the RA subgroup, FM prevalence was significantly higher among patients not receiving b/tsDMARDs (P = .030).
conclusionThe findings suggest that the use of b/tsDMARDs appears to be associated with a reduced prevalence of FM among patients with RA. It is believed that this study provides a window for future studies. Cite this article as: Caglayan M, Oktayoglu P, Celik Y, et al. Assessment of the concomitance of fibromyalgia in patients with axial spondyloarthritis and rheumatoid arthritis. ArchRheumatol. 2026;41(1):72-80.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.